Zynerba Pharmaceuticals, a clinical-stage pharmaceutical company based in Devon, is testing a CBD gel to help treat autism, writes Queen Muse for Philadelphia magazine.
The company currently has multiple clinical trials underway to test the effectiveness of treatments for several rare and near-rare neuropsychiatric disorders, including Fragile X Syndrome, the most common genetic cause of autism.
Zynerba’s pivotal clinical trial for its lead product, Zygel, will evaluate the effectiveness and safety of the treatment in 204 children and teenagers, between the ages of three and 17, with Fragile X Syndrome. The trial is currently enrolling patients in the U.S., Australia, and New Zealand.
Zygel is the only pharmaceutically manufactured CBD that is formulated as a gel and can be delivered through the skin into the circulatory system.
The company decided to work on a Fragile X Syndrome treatment due to the lack of options.
“When we looked at what’s available and saw that there was nothing available for Fragile X Syndrome, we knew this was a high unmet need,” said Zynerba’s chief executive officer, Armando Anido. “It gives us a nice opportunity to make a huge difference for these patients who have no other treatment options.”
Read more about Zynerba Pharmaceuticals in Philadelphia magazine here.